NovoCure Ltd (NVCR) · Oct 29, 2026 · Earnings

NovoCure earnings beat as 2026 guidance rises

Beat — EPS $(0.09) vs ~$0.23 loss consensus; revenue $193.4M vs ~$182.3M

NovoCure earnings beat Q3 revenue and EPS expectations, with adjusted EBITDA turning positive and 2026 financial guidance raised.

NovoCure is commercializing wearable Tumor Treating Fields across its established Optune Gio franchise while scaling newer Optune Lua and Optune Pax products into additional cancer markets. The business is trying to convert that broader product portfolio into sustained growth and profitability; prior company guidance targeted $710M–$725M of 2026 revenue and positive adjusted EBITDA.

This was a clear earnings beat, not merely a favorable presentation. Third-quarter revenue reached $193.4 million, well above the published consensus of roughly $182.3 million, while adjusted EPS was a $0.09 loss versus an expected loss of about $0.23. The revenue beat matters because consensus had anticipated a slight sequential decline from Q2, whereas the filing delivered another record quarter.

Q3 2026Q3 2025Consensus
Net revenue (Financial Statements)$193.4M (+15.7%)$167.2M$182.3M
Diluted EPS (Financial Statements)$(0.09)$(0.33)$(0.23)
Gross margin (Financial Highlights)77%73%
Adjusted EBITDA (Adjusted EBITDA reconciliation)$15.7M$(3.0M)
Active patients (Active patients at period end)5,260 (+19.1%)4,416

The more important change is operating leverage. Revenue grew 15.7% year over year while gross margin expanded to 77%, helped by higher patient volumes, better array utilization and manufacturing efficiencies. Sales and marketing and general and administrative expenses both declined, allowing adjusted EBITDA to turn positive at $15.7 million from a $3.0 million loss a year earlier. The company said, “Gross margin for the quarter was 77% compared to 73% in the prior year.” 〔0〕

The product expansion is beginning to show up in the installed base. Total active patients rose to 5,260 from 4,416 a year earlier, with Optune Pax contributing 276 patients after having none in the year-ago comparison and Optune Lua reaching 255 patients. That supports the strategy of reducing reliance on Optune Gio, although the filing does not provide separate product revenue, so the newer franchises remain early-stage contributors. The filing describes the quarter as driven by “continued growth in our Optune Gio business and our growing portfolio of products launching in new markets.”

Guidance moved higher, but the filing does not disclose the revised total range. Management explicitly said, “Based on the results from this quarter, we have raised our financial guidance for 2026,” while the release only specifies assumptions including mid-to-high single-digit Optune Gio growth, $30 million–$34 million of combined Lua and Pax revenue, and gross margins in the mid-to-high 70s. 〔1〕 The direction is clearly favorable, but the magnitude cannot be assessed from the filing alone.

The clinical pipeline remains an important second leg, not the main quarterly driver. Research and clinical spending increased 8% to $58.1 million, primarily because of KEYNOTE D58, while Novocure also entered a clinical-trial collaboration and supply agreement with Verastem Oncology for pancreatic cancer. The agreement broadens the development opportunity but does not yet create reported revenue or establish clinical success.

Bottom line: This filing materially advances NovoCure’s story: the commercial portfolio is growing faster than expected, margins are improving, adjusted EBITDA has turned positive, and management raised 2026 guidance. The key question now shifts from whether the business can grow to whether the newer products and pipeline can make that profitability durable.

What to watch next

Q4 2026 FDA decision on brain-metastases application

Original filing on SEC EDGAR

More NovoCure Ltd news

NovoCure earnings beat as 2026 guidance rises | NVCR Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.